New pill could offer hope to bowel cancer and gastrointestinal stromal tumor patients after failure of standard treatments

November 21, 2012

Globally, nearly 1.25 million people are diagnosed with bowel cancer every year, and in at least 50% of patients the cancer spreads to other parts of their body (which doctors refer to as the cancer becoming metastatic). Metastatic bowel cancer tends not to be treatable by surgery, and although there are a number of existing drugs which can be used to treat the cancer, resistance develops eventually to all therapies, and patients then have poor prognosis.

Gastrointestinal stromal tumours (GISTs) belong to a type of cancer known as soft tissue sarcomas, and although they are relatively rare, there are thought to be at least 8000 new cases in Europe every year. While GISTs can be surgically removed in their early stages, more than 40% of cases recur and begin to spread. There are currently only two drugs - 'molecular targeted' therapies called imatinib and sunitinib - approved to treat GISTs.

In one trial, led by Professor Eric Van Cutsem, at the University Hospitals Leuven in Belgium, and Professor Axel Grothey at the Mayo Clinic, Rochester, Minnesota, USA, researchers assessed the effect of regorafenib on patients with bowel cancer which was progressing after the patients had received all available standard therapies (classic chemotherapy, and other targeted agents). In a group of 760 patients, 505 were assigned a daily 160mg dose of regorafenib for three weeks, followed by a one week break, and 255 patients were assigned a placebo delivered to the same schedule. The cycle was then repeated if necessary. All patients received the best available supportive care throughout the trial.

The trial participants were monitored for up to 16 months after the trial began, and the researchers found that overall, patients who received regorafenib had an overall survival of an average (median) of 6.4 months, compared to 5.0 months for those who were given placebo. The authors noted also that regorafenib delayed progression compared to placebo, and more frequently controlled metastatic disease compared to placebo.

According to Professor Van Cutsem, "Our results show that in patients with progressive bowel cancer which still progresses after standard treatments, regorafenib can significantly prolong survival, compared with placebo. This provides further evidence for the role of targeted therapies, and should offer hope for a new standard of care in bowel cancer patients who have no other treatment options left to them. In future, we hope to find subgroups of patients, based on molecular markers, who may experience significantly better survival times on regorafenib and are likely to benefit from it the most."*

In another trial, researchers led by Professor George Demetri, at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, examined the effect that regorafenib had on patients with GIST which was worsening, despite prior treatment with both imanitib and sunitinib. In a group of 199 patients, 133 received a daily 160mg dose of regorafenib for three weeks, followed by a one week break, and 66 patients received a matching placebo delivered to the same schedule, with the cycle of treatment repeated as long as benefit was maintained. Again, all patients received the best available supportive care throughout the trial. Trial participants were monitored for at least 12 months after the trial began, and those patients who started by receiving regorafenib had an average (median) progression-free surivival time of 4.8 months, compared to 0.9 months to those in the matched placebo group.

According to Professor Demetri, "When added to best supportive care, regorafenib significantly improves disease control, as measured by progression-free survival time, in patients with GIST after progression following failure of all other therapies. We know that regorafenib can inhibit many of the mutated proteins and abnormal signals which cause this cancer, and the next step will be to investigate the molecular mechanisms by which this new treatment can control GIST after resistance appears to other 'targeted therapy' drugs for this aggressive malignancy."*

In both trials, regorafenib resulted in a high rate of adverse effects, the most severe of which were hypertension (high blood pressure), fatigue, diarrhoea and hand-foot skin reaction (reddening, swelling, numbness, and peeling of the skin). These effects were expected from experiences of earlier regorafenib trials, and the authors state that, in most cases, they were able to manage them by reducing or interrupting the dose.

Writing in a linked Comment, Professor David Cunningham and Dr Tom Waddell, of The Royal Marsden Hospital in Sutton, UK, state that, "On the basis of the reported data from these two clinical trials, regorafenib would seem to have a future in the treatment of gastrointestinal malignant disease. In the relatively rare GIST, the case for routine use of this drug in patients who have failed imatinib and sunitinib is strong, despite the apparent absence of a benefit in terms of overall survival, which is probably attributable to planned extensive crossover to regorafenib. By contrast, and somewhat paradoxically, in colorectal cancer for which a statistically significant improvement in survival is reported, the overall clinical effect of the drug seems to be more modest and the case is less compelling, but would be greatly enhanced by the identification of a biomarker that allows selection of the subset of patients who really benefit from regorafenib."

*Quotes direct from authors and cannot be found in text of Articles.


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to